NIPS
Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year
Premium
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
Natera Revenues Grow 35 Percent in Q4
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
Myriad Genetics Bets Fetal DNA Enrichment Method Will Further Increase Uptake of NIPS Test
In a study involving 1,300 blood samples from pregnant women, Myriad researchers demonstrated that their method could increase the fetal fraction for almost all.
Natera Expects Further Growth in NIPT as it Expands Use Cases for Cancer, Transplant Tests
The company plans to show new data for its Signatera oncology test at three upcoming conferences this year, including in breast cancer and bladder cancer.
Natera Q3 Revenues Up 26 Percent on Increased Testing Volumes
Product revenues increased 39 percent year over year to $93.3 million, while license and other revenues were down 56 percent to $4.9 million.
Oct 26, 2020
Yourgene H1 Revenues Up 5 Percent
Sep 11, 2020
Natera Prices $250M Public Stock Offering
May 6, 2020
Natera Q1 Revenues Grow 41 Percent
Apr 20, 2020
Yourgene Health Fiscal 2020 Revenues Up 86 Percent
Apr 14, 2020
Natera Prices $250M Senior Notes Offering
Nov 8, 2019
Sep 13, 2019